Analyzing Cardinal Health (CAH) & biOasis Technologies (BIOAF)

Cardinal Health (NYSE:CAH) and biOasis Technologies (OTCMKTS:BIOAF) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.

Valuation and Earnings

This table compares Cardinal Health and biOasis Technologies’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cardinal Health $136.81 billion 0.12 $256.00 million $5.00 11.06
biOasis Technologies $460,000.00 29.00 -$4.12 million N/A N/A

Cardinal Health has higher revenue and earnings than biOasis Technologies.


This table compares Cardinal Health and biOasis Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cardinal Health 0.19% 22.59% 3.80%
biOasis Technologies -1,517.77% -407.59% -264.48%


Cardinal Health pays an annual dividend of $1.91 per share and has a dividend yield of 3.5%. biOasis Technologies does not pay a dividend. Cardinal Health pays out 38.2% of its earnings in the form of a dividend. Cardinal Health has increased its dividend for 13 consecutive years.

Institutional & Insider Ownership

90.6% of Cardinal Health shares are held by institutional investors. 1.1% of Cardinal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Cardinal Health and biOasis Technologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardinal Health 2 7 2 0 2.00
biOasis Technologies 0 0 0 0 N/A

Cardinal Health currently has a consensus target price of $60.27, suggesting a potential upside of 8.97%. Given Cardinal Health’s higher probable upside, equities research analysts plainly believe Cardinal Health is more favorable than biOasis Technologies.

Volatility & Risk

Cardinal Health has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, biOasis Technologies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.


Cardinal Health beats biOasis Technologies on 12 of the 14 factors compared between the two stocks.

Cardinal Health Company Profile

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States and internationally. It provides medical products and pharmaceuticals, and solutions that enhance supply chain efficiency for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. The company operates through two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. It also provides services to support the development, marketing, and distribution of specialty pharmaceutical products, as well as pharmacy management, and medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products. It also distributes a range of national brand products; and medical products to patients' homes, as well as provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.

biOasis Technologies Company Profile

biOasis Technologies, Inc. is a biopharmaceutical company focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include Transcend program as its proprietary carrier, p97, and components thereof, to deliver therapeutics and imaging agents across the blood brain barrier. The company was founded by Robin B. Hutchison on November 3, 2006 and is headquartered in Vancouver, Canada.

Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit